Healthcare-associated Pneumonia
📧 Sign up to get email alerts when something new happens for Healthcare-associated Pneumonia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-02-23EMA Authorised: Emblaveo (avibactam;aztreonam) — Pfizer Europe MA EEIG
The EMA authorised Emblaveo (avibactam/aztreonam) for treating certain Gram-negative bacterial infections, including urinary tract infection…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study [NA]
A clinical trial comparing HYDROcortisone to placebo for severe hospital-acquired pneumonia in ICU patients; the study is currently recruiti…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
A completed Brazilian clinical trial evaluated the application of Ventilator-Associated Event (VAE) criteria to patients with Ventilator-Ass…
-
CLINICAL_TRIALS trial_result · 2024-08-19Clinical Trial Update: Trial of Antimicrobial Restraint in Presumed Pneumonia [NA]
A completed clinical trial update describing a study on antimicrobial restraint in presumed pneumonia.
-
EMA approval · 2024-03-22EMA Authorised: Exblifep (cefepime dihydrochloride monohydrate;Enmetazobactam) — Advanz Pharma Limited
Exblifep has been authorised for multiple infections including urinary tract infections, pyelonephritis, healthcare-associated pneumonia, an…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens [Phase 3]
Phase 3 trial evaluating Cefiderocol (S-649266) versus best available therapy for severe infections due to carbapenem-resistant Gram-negativ…
-
CLINICAL_TRIALS trial_result · 2020-11-13Clinical Trial Update: Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens [Phase 3]
Phase 3 clinical trial of Cefiderocol for healthcare-associated pneumonia and hospital-acquired pneumonia has completed with results posted …
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia
Clinical trial update describing characteristics and microbiology of healthcare associated pneumonia; results posted after completion.
-
CLINICAL_TRIALS withdrawal · 2019-10-09Clinical Trial Update: Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria [Phase 2, Phase 3]
A randomized-controlled trial evaluating a combination antibiotic for gram-negative infections (bacteremia and healthcare-associated pneumon…
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) [Phase 3]
Phase 3 safety and efficacy study of ceftolozane/tazobactam for ventilated nosocomial pneumonia has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: Drug Resistance Factors In Healthcare-associated Pneumonia
The clinical trial update notes that the study examining drug resistance factors in healthcare-associated pneumonia has completed.
-
CLINICAL_TRIALS research · 2011-01-20Clinical Trial Update: An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia
An open-label randomized trial compares cefoperazone/sulbactam to cefepime for the treatment of hospital-acquired pneumonia and healthcare-a…
-
CLINICAL_TRIALS trial_result · 2009-02-13Clinical Trial Update: Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia [Phase 2]
A Phase 2 trial comparing intravenous iclaprim to vancomycin for hospital-acquired, ventilator-associated, or healthcare-associated pneumoni…
-
CLINICAL_TRIALS trial_result · 2008-02-07Clinical Trial Update: Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients [Phase 4]
A Phase 4 trial assessing oral decontamination with chlorhexidine or potassium permanganate in ICU patients to prevent pneumonia; the study …